At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Perampanel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Perampanel on Peritumoral Hyperexcitability and Seizure Control in Newly Diagnosed High Grade Glioma
In Brief
A Phase 2 clinical trial evaluating Perampanel and Standard of Care for Glioma, Malignant and 2 related conditions. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this research study is to learn more about seizures in people with primary brain tumors. It will evaluate whether an antiseizure medication decreases hyperexcitability activity around tumors and prevents seizures. The procedure and study drug involved in this study are: * Electrocorticography * Perampanel (Fycompa)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioma, Malignant, Surgery, Seizures
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Eisai Inc.
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartNov 2020
Primary CompletionMay 2023
TodayJul 2026
First PostedAug 4, 2020
Enrollment StartNov 5, 2020
Primary CompletionMay 16, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.9 years ago
Interventions
Perampaneldrug
Tablet taken orally 1x daily.
Standard of Caredrug
Predetermined standard of care drug and dosing